The authors describe the growth characteristics of human mesenchymal stem cells cultured in a stirred-tank bioreactor.
A simple, sensitive, and universal platform for identification and quantification of trace-level protein impurities in biotherapeutics is described.
This article is the third and final in a series designed to offer leaders and managers at all levels in the industry a road map to excellence in human performance and human error prevention.
Can postapproval FDA filings immunize pharma companies from patent lawsuits?
Successful management of the CMO/client relationship should include open communication and trust.
In this question-and-answer discussion of "generic" biologics, the authors contend small changes in manufacturing of biologics dramatically affect the safety and efficacy of the therapeutic molecule.
The move to single-use manufacturing has prompted a paradigm shift in facility design.
A simple, sensitive, and universal platform for identification and quantification of trace-level protein impurities in biotherapeutics is described.
Traditional project decision-making vs. a QbD approach.
A new downstream purification platform using a salt-tolerant membrane adsorber.
Advances in cell culture media technology have helped achieve safer biologics.
Cellular and gene therapy fields are currently on track for, if not already experiencing, a serious capacity crunch.
The authors describe a new assembly for bulk and final drug product filling operations.
Operational planning and early cost analyses are key to generating optimal, robust, and economical commercial processes.
The authors describe a novel means to control ice nucleation using a sterile cryogenic ice fog.
The authors describe a simple method to remove endotoxins from highly viscous formulations.
A novel approach to sterile drug product manufacturing uses a single-use assembly in a multi-product final filling suite with isolator technology.
Webinar Date/Time: Thu, Sep 5, 2024 11:00 AM EDT
Reauthorization of pediatric exclusivity provisions looms in 2012 and debates begin anew.
The Madrid Protocol offers companies another option for trademark registration on a global scale.
Chromatography modeling can enhance bioprocessing efficiencies.
Partnering with CDMOs can help bridge the innovation gap.
Molecular mimicry is a common, but undesirable, property of disease proteins. Sequence similarities between cancer proteins and self-proteins allow tumor cells to hide, thereby avoiding attack from the immune system. HIV uses the same evasive tactic.